Imagine the life of a yeast cell, floating around the kitchen in a spore that eventually lands on a bowl of grapes. Life is good: food for days, at least until someone notices the rotting fruit and throws them out.
As placebo spoils PhIII trial, Acadia does not intend to stage further Nuplazid studies in schizophrenia
After years of trying to expand the market territory for Nuplazid, Acadia Pharmaceuticals might have hit a dead end, with a Phase III failure in
March 13, 2024